Why the study?
Current recommendations support vitamin K antagonists for left ventricular thrombus, but limited data exist regarding the use of direct oral anticoagulants.
Do DOACs improve LVT resolution and prevent thromboembolic events compared to VKAs in patients with left ventricular thrombus?
Do DOACs improve LVT resolution and prevent thromboembolic events compared to VKAs in patients with left ventricular thrombus?
DOACs appear more efficacious than VKAs for achieving left ventricular thrombus resolution without increasing the risk of thromboembolic events or major bleeding.
No takes yet. Share an insight, caveat, or question.
DOACs appear comparable to VKAs for LVT; supports use as alternative but leaves open need for dedicated RCTs.
Burmeister et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: